L. Shulman

807 citations

14 papers · 591 indexed · h-index 9

Impact in

Pathology and Forensic Medicine top 5%
- Lymphoma Diagnosis and Treatment
- Breast Lesions and Carcinomas
Cancer Research top 10%
- Breast Cancer Treatment Studies

Papers in

Cancer Research 5
- Breast Cancer Treatment Studies 5
- Cancer Genomics and Diagnostics 2
Oncology 8
- Cancer Treatment and Pharmacology 5

Co-authors: Barbara Silver Steven E. Come P Mauch Abram Recht T.J. Eberlein Anthony Abner James L. Connolly Daniel Hayes
Journals: Journal of Clinical Oncology (5 papers)International Journal of Radiation Oncology*Biology*Physics (3 papers)Cancer Research (2 papers)Annals of Oncology (1 paper)Blood (1 paper)
Partner nations: United States

In The Last Decade

L. Shulman

14 papers receiving 567 citations

Peers

Countries citing papers authored by L. Shulman

Since Specialization

Citations

This map shows the geographic impact of L. Shulman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Shulman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Shulman more than expected).

Fields of papers citing papers by L. Shulman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Shulman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Shulman. The network helps show where L. Shulman may publish in the future.

Co-authorship network

The 25 scholars most cited alongside L. Shulman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with L. Shulman Line = papers co-authored together L. Shulman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work
1	Inherited genetic variation in EPHA5, FGD4, and NRDG1 and paclitaxel (P)-induced peripheral neuropathy (PN): Results from a genome-wide association study (GWAS) in CALGB 40101. Journal of Clinical Oncology ·Deanna L. Kroetz, Ronald M. Baldwin, Kouros Owzar, Chunhui Jiang, Hitoshi Zembutsu, Michiaki Kubo, S. Aji, L. Shulman, Mark J. Ratain, (unknown)	2010	8
2	Abstract S6-3: Four vs 6 Cycles of Doxorubicin and Cyclophosphamide (AC) or Paclitaxel (T) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Nodes: CALGB 40101 — A 2x2 Factorial Phase III Trial: First Results Comparing 4 vs 6 Cycles of Therapy Cancer Research ·L. Shulman, C. Cirrincione, DA Berry, JAPIE BRITS, 陈平周, 精慈宮川, Simona Di Martino, JN Atkins, Clifford A. Hudis, EP Winer	2010	4
3	GRB7-dependent pathways are potential therapeutic targets in triple-negative breast cancer. Cancer Research ·貴志三谷, Robert P. Gray, LJ Goldstein, BH Childs, Roberto Bugarini, Simone M. Rowley, Jennifer H.E. Baker, S. Shak, S Badve, Usha Sood, EA Perez, L. Shulman, Sabata Martino, Katherine Corbett, NE Davidson	2009	3
4	Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. PubMed ·P Mauch, Sinval Ferreira, Karen Marcus, L. Shulman, Shankari Banerjee, N J Tarbell, Barbara Silver, Harel Weinstein, Steven E. Come, G P Canellos, C. Norman Coleman	2006	66
5	Primary systemic treatment of advanced Hodgkin’s disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up Annals of Oncology ·George P. Canellos, Jeremy Gollub, Donna Neuberg, Peter Mauch, L. Shulman	2003	19
6	Phase I Trial of Intraperitoneal Injection of theE1B-55-kd-Gene–Deleted Adenovirus ONYX-015 (dl1520) Given on Days 1 Through 5 Every 3 Weeks in Patients With Recurrent/Refractory Epithelial Ovarian Cancer Journal of Clinical Oncology ·P. Vasey, L. Shulman, Susana M. Campos, Jo Ann Davis, M. Gore, Stephen Johnston, David H. Kirn, V J O'Neill, Neelam Siddiqui, Michael V. Seiden, Stuart Kaye	2002	41
7	Concurrent CMF and reduced-dose radiation therapy (RT) in patients with early-stage breast cancer: updated results of a prospective trial International Journal of Radiation OncologyBiologyPhysics ·Jennifer R. Bellon, Steven E. Come, Rebecca Gelman, Thorben Ewald Bruns, L. Shulman, B. Silver, Jay R. Harris, A. Recht	2002	12
8	Sequencing of chemotherapy and radiation therapy for patients with early stage breast cancer: updated results of a prospective randomized trial International Journal of Radiation OncologyBiologyPhysics ·Jennifer R. Bellon, SE Come, Rebecca Gelman, I. Craig Henderson, L. Shulman, B. Silver, Jay R. Harris, Abram Recht	2001	29
9	Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. Journal of Clinical Oncology ·Stephan Bodis, Madeleine D. Kraus, Geraldine Pinkus, Barbara Silver, Marshall E. Kadin, G P Canellos, L. Shulman, N J Tarbell, Peter Mauch	1997	68
10	An information system to improve the safety and efficiency of chemotherapy ordering. PubMed ·Luísa Fortes Paina, J. P. Seta, 林娟芳, John Fanikos, Marni Storey-Kuyl, L. Shulman	1996	14
11	Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome Blood ·P Mauch, Sinval Ferreira, 莊美華, CN Coleman, L. Shulman, Shankari Banerjee, Steven E. Come, Barbara Silver, Canellos Gp, NJ Tarbell	1996	148
12	14 Sequencing of chemotherapy (CT) and radiotherapy (RT) following conservative surgery (CS) for patients with early-stage breast cancer: Results of a randomized trial International Journal of Radiation OncologyBiologyPhysics ·Abram Recht, SE Come, Barbara Silver, Rebecca Gelman, D F Hayes, L. Shulman, I. Craig Henderson, Jay R. Harris	1995	7
13	Improved survival in patients with limited stage IIIA Hodgkin's disease treated with combined radiation therapy and chemotherapy. Journal of Clinical Oncology ·Karen Marcus, Sinval Ferreira, C. Norman Coleman, L. Shulman, David I. Rosenthal, G P Canellos, Peter Mauch	1994	8
14	Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. Journal of Clinical Oncology ·Anthony Abner, Abram Recht, T.J. Eberlein, Nikitha Cherayil, L. Shulman, Daniel Hayes, James L. Connolly, S J Schnitt, Barbara Silver, Jeffrey R. Harris	1993	164

About L. Shulman

L. Shulman is a scholar working on Cancer Research, Oncology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Hepatology, having authored 14 papers that have together received 591 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (5 papers), Cancer Treatment and Pharmacology (5 papers), Lymphoma Diagnosis and Treatment (5 papers), Multiple and Secondary Primary Cancers (4 papers), Lung Cancer Treatments and Mutations (3 papers), BRCA gene mutations in cancer (2 papers), Cancer Genomics and Diagnostics (2 papers) and Advanced Breast Cancer Therapies (1 paper). The work is most often cited by research in Pathology and Forensic Medicine (346 citations), Cancer Research (229 citations), Oncology (245 citations), Neurology (65 citations) and Genetics (43 citations). L. Shulman has collaborated with scholars based in United States. Frequent co-authors include Barbara Silver, Steven E. Come, P Mauch, Abram Recht, T.J. Eberlein, Anthony Abner, James L. Connolly, Daniel Hayes, S J Schnitt and Jeffrey R. Harris. Their work appears in journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics, Cancer Research, Annals of Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact